Aron M. Knickerbocker
Chief Executive Officer bei Aulos Bioscience, Inc.
Aktive Positionen von Aron M. Knickerbocker
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
KAHR Medical Ltd.
KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | Chairman | - | - |
Director/Board Member | 05.10.2020 | - | |
Aulos Bioscience, Inc.
Aulos Bioscience, Inc. BiotechnologyHealth Technology Aulos Bioscience, Inc. operates as a biotechnology firm. The company is headquartered in Cambridge, MA. | Director/Board Member | 15.03.2021 | - |
Chief Executive Officer | 15.03.2021 | - | |
President | 15.03.2021 | - | |
Phenomic AI, Inc.
Phenomic AI, Inc. Packaged SoftwareTechnology Services Phenomic AI, Inc. develops machine-learning technology for drug discovery. It provides application of deep learning to biological imaging screens and chemo-informatics. The company was founded by Oren Kraus and Sam Cooper and is headquartered in Toronto, Canada. | Director/Board Member | - | - |
Karriereverlauf von Aron M. Knickerbocker
Ehemalige bekannte Positionen von Aron M. Knickerbocker
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
FIVE PRIME THERAPEUTICS, INC. | Director/Board Member | 17.10.2013 | 19.09.2019 |
Chief Executive Officer | 01.01.2018 | 19.09.2019 | |
Chief Operating Officer | 08.09.2016 | 01.01.2018 | |
Investor Relations Contact | 01.09.2009 | - | |
Corporate Officer/Principal | 01.09.2009 | - | |
President | 01.01.2018 | 19.09.2019 | |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01.01.2005 | 01.09.2009 |
ALZA CORPORATION | Corporate Officer/Principal | 01.01.2000 | 01.01.2001 |
AMGEN INC. | Corporate Officer/Principal | 01.01.1996 | 01.01.2000 |
RAYZEBIO, INC. | Chief Executive Officer | - | - |
Chairman | - | - | |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - | - |
Ausbildung von Aron M. Knickerbocker
Washington University in St. Louis | Undergraduate Degree |
University of Michigan | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 10 |
Israel | 2 |
Kanada | 2 |
Operativ
Corporate Officer/Principal | 5 |
Director/Board Member | 4 |
Chief Executive Officer | 3 |
Sektoral
Health Technology | 9 |
Consumer Services | 3 |
Technology Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
AMGEN INC. | Health Technology |
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
RAYZEBIO, INC. | Health Technology |
Private Unternehmen | 6 |
---|---|
ALZA Corp.
ALZA Corp. Pharmaceuticals: MajorHealth Technology ALZA Corp. provides drug delivery solutions and develops pharmaceutical products. The company applies its delivery technologies to develop pharmaceutical products with enhanced therapeutic value for its own portfolio and for many of the world's leading pharmaceutical companies. The company was founded by Martin Gerstel and Alejandro Zaffaroni in 1968 and is headquartered in Vacaville, CA. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
KAHR Medical Ltd.
KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | Health Technology |
Phenomic AI, Inc.
Phenomic AI, Inc. Packaged SoftwareTechnology Services Phenomic AI, Inc. develops machine-learning technology for drug discovery. It provides application of deep learning to biological imaging screens and chemo-informatics. The company was founded by Oren Kraus and Sam Cooper and is headquartered in Toronto, Canada. | Technology Services |
Aulos Bioscience, Inc.
Aulos Bioscience, Inc. BiotechnologyHealth Technology Aulos Bioscience, Inc. operates as a biotechnology firm. The company is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Aron M. Knickerbocker
- Erfahrung